The Soluble Folate Receptor in Autism Spectrum Disorder: Relation to Autism Severity and Leucovorin Treatment
Abstract
Autism spectrum disorder (ASD) is a heterogeneous neurodevelopmental disorder with life-long consequences that affects up to 1 in 44 children. Treatment with leucovorin (folinic acid), a reduced form of folate, has been shown to improve symptoms in those with ASD and folate pathway abnormalities in controlled clinical trials. Although soluble folate binding proteins (sFBPs) have been observed in the serum of some patients with ASD, the significance of this finding has not been studied. Here, we present a cohort of ASD patients with sFBPs. These patients had severe ASD and were medically complex. Using baseline controlled open-label methodology and standardized assessments, these patients were found to improve in both core and associated ASD symptoms with leucovorin treatment. No adverse effects were related to leucovorin treatment. This is the first report of the sFBPs in ASD. This study complements ongoing controlled clinical trials and suggests that leucovorin may be effective for children with ASD who are positive for sFBPs. Further, sFBPs might be important biomarkers for treatment response to leucovorin in children with ASD. This study paves the way for further controlled studies for patients with sFBPs.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Dec 08, 2022
- Source ID
- 10.3390/jpm12122033
Entities
People
- Adrienne C Scheck
- Alison Lane
- Ashley Worner
- Brianna A. Werner
- Daniel A Rossignol
- Edward V. Quadros
- Heidi L. Collins
- Patrick J. Mccarty
- Richard E Frye
- Steven J. Adelman
Organizations
- Autism Speaks
- Brain Foundation
- National Institutes of Health
- United States Department of Defense